Mauro Krampera
Docenti di ruolo di Ia fascia
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (25)
Year:
2026
Background/Objectives: Treatment of HIV-associated lymphoma (HIV-Ly) with autologous stem cell transplantation (ASCT) has shown a surprisingly low relapse rate in several series. The aim of this study was to compare the clinical outcomes of HIV-Ly and lymphomas in the general population receiving ASCT. Methods: We compared two series of consecutive HIV-positive and HIV-negative patients, based on a 1:1 propensity score analysis, matching for age, sex, histology, disease status and prior therapies. Results: After propensity matching we identified a final population of 88 patients (44 HIV-positive vs. 44 HIV-negative). All HIV-positive patients received combination antiretroviral therapy (cART). With a median follow-up of 51 months, PFS was significantly higher in HIV-positive patients (4-year PFS 81% and 51%, in HIV-positive and HIV-negative patients, respectively, p = 0.027). Four-year OS was 81% for HIV-positive and 67% in HIV-negative patients (p = 0.15). The relapse rate was significantly higher in HIV-negative patients (36% vs. 23%) (p = 0.04). Conclusions: Our results clearly show that ASCT is an effective curative option for HIV-Ly, with better PFS and a lower relapse rate compared to patients without HIV. A favorable effect of ASCT on HIV infection and immune system recovery, potential off-target effects of cART or other yet unknown factors may account for this observation.
Year:
2026
Year:
2026
Year:
2026
Primary cutaneous B‐cell lymphomas (CBCL) represent a clinically and biologically heterogeneous group of extranodal non‐Hodgkin lymphomas confined to the skin at the time of diagnosis. They account for approximately 25% of all primary cutaneous lymphomas and are subclassified into distinct entities according to the World Health Organization—European Organization of Research and Treatment of Cancer (WHO–EORTC) classification and International Consensus Classification (ICC). including primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT), intravascular large B‐cell lymphoma (IVLBCL) and Epstein–Barr virus–positive mucocutaneous ulcer (EBVMCU). These subtypes differ significantly in clinical behavior, histopathological features, molecular alterations, and prognosis. Indolent forms such as PCFCL and PCMZL are typically managed with local therapies and are associated with an excellent prognosis. In contrast, aggressive variants such as PCDLBCL‐LT require systemic treatment and are linked to poorer outcomes. EBVMCU, despite its alarming histological appearance, generally follows a benign and self‐limiting course. This review provides an updated overview of the current diagnostic criteria, clinical management strategies, and emerging molecular insights for each CBCL subtype. It also emphasizes the importance of a multidisciplinary approach and discusses the challenges of prognostication, along with the evolving but still limited role of innovative therapies.
Year:
2026
Year:
2026
Dural-based lymphomas are rare extranodal non-Hodgkin lymphomas that span from indolent primary dural entities, most commonly extranodal marginal zone (mucosa-associated lymphoid tissue) lymphoma, to aggressive variants that are primary or represent secondary involvement from systemic lymphoma. They overlap radiologically with benign meningiomas, dural metastases, and immune-mediated pachymeningitis, creating a risk of anchoring bias, delayed diagnosis, and unnecessarily extensive resections when limited tissue sampling would be sufficient for diagnosis. We conducted a structured narrative review to synthesize the epidemiology, clinico-pathological classification, imaging phenotypes, and management principles of dural lymphomatous disease. This study will especially focus on primary dural lymphoma (PDL) with additional discussion of secondary dural involvement. Emphasis is placed on the clinical value of a multiparametric diagnostic approach that integrates computed tomography contrast-enhanced magnetic resonance imaging with functional techniques, and fluorodeoxyglucose positron emission tomography/computed tomography for systemic staging and for distinguishing truly localized primary dural lymphoma from secondary involvement. Potential diagnostic pitfalls related to somatostatin receptor–based tracer uptake will also be discussed. We introduced a pragmatic operational framework based on four clinico-biological clusters, translated into a step-by-step decision algorithm that prioritizes timely biopsy and comprehensive hematologic staging to guide surgical strategy. Given the absence of dedicated, multidisciplinary guidance for dural-based lymphomas, this algorithm is intended as a reproducible foundation for consensus recommendations and future multicenter validation.
Year:
2026
Acute Myeloid Leukemia is mainly a disease of the elderly: however, the knowledge on the outcomes of treatment in core binding factor AML (CBFAML) in older population, is limited. We retrospectively collected data on 229 patients with CBF- AML followed long-term in the last two decades. A 5-year overall survival (OS) of 44.2% (95%CI, 39.9-47.5) and a 5-year event – free survival (EFS) of 32.9% (95%CI, 25.5-40.1) was observed. In a subgroup of >70-year patients who completed intensive therapy (induction + >3 courses of consolidation including autologous stem cell transplant: 10 patients) the median EFS was 11.8 months (95%CI, 9.4 – 15.2) and OS was 40.0% (95%CI, 36.4 – 44.1) at 5yr. In univariate analysis, age >70 (hazard ratio (HR) 1.78, [95%CI, 1.15 – 2.54], p=.008), failure to achieve remission following induction (HR, 8.96 [95%CI, 5.5 – 13.8], p=<.0001), no consolidation therapy (HR, 0.75 [95%CI, 0.47 – 1.84], p=.04) and less than 3 cycles of consolidation (HR, 1.48 [95%CI, 0.75 – 3.2], p=.0004), predicted poorer EFS. Our study shows that intensive therapy, in selected older CBF-AML patients, leads to longer survival. Achieving a CR seems to be the most important first step and at least 3 cycles of consolidation, an important second one. The analysis suggests that these patients should not be excluded from studies with intensive therapies.
Year:
2025
Background/Objectives: Three-dimensional (3D) in vitro cell culture models have recently stimulated great interest since they may have more pre-clinical value than conventional in vitro 2D models. In fact, 3D culture models may mimic the in vivo biophysical 3D structure of tumors and cell-to-cell interaction, thereby representing a more useful approach to testing drug responses. In this study we have developed a 3D culture model of an EBV+/CD30+cell line, D430B, previously characterized as an Anaplastic Large Cell Lymphoma of B phenotype (B-ALCL), to determine the cytotoxic activity of the antibody–drug conjugate Brentuximab Vedotin. Methods: By using of ultra-low attachment plates, we developed D430B spheroids that appeared particularly homogenous in terms of growth and size. Results: Brentuximab Vedotin treatment (1 to 20 μg/mL) turned out to be significantly cytotoxic to these cells, while the addition of the anti-CD20 chimeric antibody Rituximab (10 μg/mL) appeared almost ineffective, even though these cells express CD20. Moreover, when we co-cultured D430B cells with stromal cells (HS5), to re-create a microenvironment representative of neoplastic cell/mesenchymal cell interactions within the lymph node, we observed a significant, although faint, protective effect. Conclusions: This simple and reproducible method of generating D430B-ALCL spheroids to evaluate their response to Brentuximab Vedotin treatment, as here described, may provide a valuable preliminary tool for the future pre-clinical screening of patients’ primary lymphoma cells or the development of novel therapies for this type of pathology and related diseases.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (47)
Cristina Santoro
Sapienza University of Rome
Girolamo Pelaia
Professor of Respiratory Medicine
Magna Graecia University
Simona D'Amore
Ricercatori a tempo determinato
University of Bari Aldo Moro
Daniela de Totero
Ospedale Policlinico San Martino
Armando Santoro
Professore
Humanitas University
Angelo Vacca
-
Alessandro Re
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Pellegrino Musto
Full Professor of Hematology
University of Bari Aldo Moro
Paola ROSSI
Professor
University of Pavia
Federica Cavallo
University of Turin
Linda Bussini
Assistant Professor
IRCCS Humanitas Research Hospital
Monica Bocchia
University of Siena
Marco Musso
Ricercatore sanitario
Ospedale Policlinico San Martino
Lorenzo Cosmi
Full Professor of Internal Medicine
University of Florence
Massimo Massaia
Associate Professor of Hematology
Università degli Studi di Torino
Roberto CHIGNOLA
Associate professor
University of Verona
John C. Byrd
UPMC Hillman Cancer Center
Valerio De Stefano
Full Professor of Hematology
Università Cattolica del Sacro Cuore
Massimiliano BONIFACIO
University of Verona
Paolo Corradini
Full Professor of Hematology
University of Milan
Francesca Palandri
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Gianenrico Senna
Head
University of Verona
PIER LUIGI ZINZANI
University of Bologna
Alessia Savoldi
Università degli Studi di Torino
Alessandra Vultaggio
section of biochemistry university of florence italy
Luca Arcaini
Director of Division of Hematology
Fondazione IRCCS Policlinico San Matteo
Effrossyni Gkrania-Klotsas
Cambridge University Hospitals NHS Foundation Trust
Giuseppe Avvisati
Full Professor of Hematolgy
Università Campus Bio-Medico di Roma
Domenico Russo
University of Brescia
Federica Sora'
professor
Università Cattolica del Sacro Cuore
Paola Parronchi
Associate Professor
University of Florence
Marco LADETTO
Associate Professor
Università degli Studi del Piemonte Orientale
Patrizia Chiusolo
Università Cattolica del Sacro Cuore
Massimo Martino
Director Stem Cell Transplant Program
Azienda ospedaliera "Bianchi-Melacrino-Morelli"
Gianluca GAIDANO
Professor of Hematology
-
Alessandra Tucci
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Ilaria Mormile
Ricercatori a tempo determinato
Università degli Studi di Napoli Federico II
MASSIMO TRIGGIANI
Professor of Medicine
University of Salerno
Silva Ljevar
Fondazione IRCCS Istituto Nazionale dei Tumori
Mario DI GIOACCHINO
YDA - Institute of Clinical Immunotherapy and advanced Biological treatments
Roberta Sommaggio
University of Padua
Francesca Wanda Rossi
Associate Professor
University of Naples Federico II
Francesco Castelli
Professor of Infectious Diseases
University of Brescia
Anna Candoni
Docenti di ruolo di IIa fascia
University of Modena and Reggio Emilia
Andrea Visentin
Assistant professor
University of Padua
ANNALISA CHIAPPELLA
Fondazione IRCCS Istituto Nazionale dei Tumori
Carlo Visco
University of Verona
Make your next move.
Prepare your application
Review drafts before you send them.